However, a high incidence of severe clinical toxicities was observed, including thrombocytopenia (99%), neutropenia (97%), grade ≥ 3 hyperbilirubinemia (23%), and grade ≥ 3 elevated alanine transaminase or aspartate transaminase levels, while no significant improvements in efficacy were shown compared to the standard of care [80]. The gene discussed is GPT; the disease is Decreased total neutrophil count.